NASDAQ$PRAX
Praxis Precision Medicines I · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Praxis Precision Medicines reported financial results for the third quarter 2023.
Praxis Precision Medicines reported a net loss of $24.6 million for the third quarter of 2023, with cash and cash equivalents totaling $101.1 million as of September 30, 2023, expected to support operations into Q1 2025. The company progressed its clinical programs, including the initiation of the Essential3 Phase 3 program for ulixacaltamide and the completion of dosing for Part 1 of the EMBRAVE study for elsunersen.
- Initiated Essential3 study for ulixacaltamide in essential tremor, with over 600 patients engaged in a pre-recruitment observational study.
- Completed final dose for Elsunersen EMBRAVE study and is seeking FDA advice on advancing development.
- PRAX-628 data in photo-paroxysmal response (PPR) is expected to be shared in the near future.
- Cash and cash equivalents totaled $101.1 million as of September 30, 2023, supporting operations into Q1 2025.
Headline financials
Revenue & EPS history
Praxis · Revenue · Quarterly
$468K
Revenue by segment
Praxis · $500K total across 1 segment · Q3 2023
- Collaboration Revenue$500K—100.0%
Forward guidance
Praxis Precision Medicines is focused on advancing its clinical programs and expects topline results from multiple studies in the near term.
Tailwinds
- Initiated Essential3, the Phase 3 program for ulixacaltamide.
- Praxis shared additional analyses from the Essential1 data set.
- Expecting topline results from the PRAX-628 Phase 2a proof-of-concept study evaluating epilepsy patients with PPR in the fourth quarter of 2023.
- Initiate a Phase 2 study to evaluate PRAX-628 for the treatment of focal epilepsy in the first half of 2024.
- Expecting topline results from the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs) in the first half of 2024.
Headwinds
- Uncertainties inherent in clinical trials.
- Reported interim data from ongoing studies and trials differing materially from final data from preclinical studies and completed clinical trials.
- The expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities.
- Regulatory approvals to conduct trials.
- Praxis’ anticipated cash runway.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-0.3%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-4.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+22.3%
Q2 2022
Best reaction
-40.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -6.4% | -22.2% | |
| Q4 2025 | +0.5% | +4.2% | -9.3% | |
| Q3 2025 | -4.7% | -2.2% | +44.4% | |
| Q1 2025 | +0.2% | -3.5% | +16.3% | |
| Q4 2024 | -40.6% | -41.8% | -40.6% | |
| Q3 2024 | +3.6% | +16.6% | -4.0% | |
| Q2 2024 | -1.1% | +2.0% | +13.3% | |
| Q1 2024 | -5.9% | -6.9% | -15.8% | |
| Q4 2023 | +6.3% | +2.3% | -7.3% | |
| Q3 2023 | +1.4% | -0.6% | +21.6% | |
| Q2 2023 | +10.8% | +17.0% | +43.9% | |
| Q1 2023 | -2.8% | -1.9% | -7.7% | |
| Q4 2022 | -4.2% | -13.0% | -77.0% | |
| Q3 2022 | -12.5% | -11.2% | -13.3% | |
| Q2 2022 | +22.3% | +33.2% | -3.4% | |
| Q1 2022 | +14.0% | +28.1% | -77.7% | |
| Q4 2021 | -1.9% | -4.2% | -22.9% | |
| Q3 2021 | +2.4% | +2.0% | -17.1% | |
| Q2 2020 | +12.7% | +35.9% | +42.8% | |
| Q2 2021 | +12.7% | +35.9% | +42.8% | |
| Q1 2021 | -16.4% | -16.1% | -20.2% | |
| Q4 2020 | -6.8% | -11.5% | -34.0% | |
| Q3 2020 | +2.3% | +18.2% | +54.7% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro